Munich, a historic city in the centre of Bavaria, is the region’s lifeblood for art, culture, technology and innovation, and from 19–23 October, it will become the stage for a historical event of another kind.

Thousands of researchers, clinicians, cancer nurses, caregivers, industry partners and patient advocates will gather in Munich for the annual European Society for Medical Oncology (ESMO) 2018 congress to learn about the latest cancer research and discuss what these developments mean for patients.

“We are excited to be part of this thriving community and to join in its shared commitment to improve the lives of patients and help shape the future of cancer care,” said Cindy Perettie, Roche Oncology Senior Vice President Global Product Strategy.

Cancer is an extremely complex disease and there is no one-size-fits-all approach, and this is why we are accelerating progress in the use of data, advanced analytics, and biomarkers in order to tailor treatments to each patient’s unique biology.
Cindy Perettie, Head of Global Product Strategy Oncology, Roche Pharmaceuticals

Shaping the future of personalised cancer care

The ability to tailor treatments to each patient’s unique biology has transformed cancer care. Our new diagnostic technologies, next-generation sequencing and precision medicines continue to push personalised healthcare forward. We are using personalised healthcare in clinical research to improve trial design and patient selection, as well as to better diagnose patients and select the best possible treatment for each person.

Driving progress in cancer immunotherapy: At ESMO, we will showcase new data from our cancer immunotherapy programme, which is fast expanding to benefit patients across a wide range of tumour types. In particular, Roche will present the first positive phase III cancer immunotherapy data for the treatment of people with triple-negative breast cancer (TNBC), a particularly aggressive form of the disease. We will also share new data on therapies for metastatic liver cancer and non-small cell lung cancer (NSCLC).

Addressing unmet needs with targeted therapies: Many patients are still being diagnosed with rare or hard-to-treat cancers that have limited therapy options. Whether it be ALK-positive NSCLC or head, neck and salivary cancer, ESMO is about working together to find immunotherapy and targeted treatment solutions for these patients.

One recent development to be highlighted is our new tumour agnostic treatments that target cancer drivers, irrespective of site of origin. Among these new treatments is one that will help cancers bearing an extremely rare gene fusion found in cholangiocarcinoma, as well as colorectal, gynaecological, neuroendocrine, salivary gland, pancreatic, sarcoma, breast and thyroid cancers, among others.

This year in Munich, we look forward to presenting research that reflects the breadth of our oncology portfolio. Follow Roche on Twitter via @Roche and keep up to date with ESMO 2018 congress news with the hashtag #ESMO2018.

Related links

Tags: Innovation